Lantheus Holdings
Update in progressLNTH (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Lantheus Holdings, Inc. develops, manufactures, and markets diagnostic and therapeutic products for heart disease, cancer, and related conditions worldwide. Its portfolio includes imaging agents like DEFINITY, Cardiolite, PYLARIFY, and Neurolite; radiopharmaceuticals such as Xenon-133 and flurpiridaz; and AI software like aPROMISE and PYLARIFY AI. It also offers therapies like PNT2002 and PNT2003, and collaborates with GE Healthcare, Curium Pharma, POINT, Regeneron, and Ratio Therapeutics. Founded in 1956 and headquartered in Bedford, MA.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.03
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.33
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!